Clinical Trials Logo

Malignant Pleural Effusion clinical trials

View clinical trials related to Malignant Pleural Effusion.

Filter by:

NCT ID: NCT06421610 Recruiting - Quality of Life Clinical Trials

OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.

Start date: September 15, 2023
Phase: Phase 1
Study type: Interventional

This study will monitor and evaluate patient and personnel safety and toxicity during the implementation and evaluation of Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) directed treatment. Furthermore, this study will focus on Quality of Life questionnaires, LENT score, and evaluate pain and breathlessness using af visual analogue scales (VAS).

NCT ID: NCT06016179 Recruiting - Clinical trials for Malignant Pleural Effusion

Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer

RIOT2
Start date: January 30, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study to find out if tocilizumab can be safely infused into chest or abdominal cavities of patients with malignancy ascites (MA) or malignant pleural effusions (MPE). Patients will have a total of 4 doses, one dose administered each week. Each dose will be greater than the previous one.

NCT ID: NCT05935696 Recruiting - Pleural Effusion Clinical Trials

A Prospective Observational Study on the Role of Transthoracic Ultrasound in Differentiating Tuberculous From Malignant Pleural Effusion

TUS-TBE
Start date: April 1, 2023
Phase:
Study type: Observational

Primary Endpoint - To assess the prevalence and diagnostic performance of pre-determined echographic features in predicting the diagnosis of TBE from MPE. - To determine the clinical, pleural fluid and echographic parameters that were different among TBE and MPE and to establish a clinical prediction model for TBE. Secondary Endpoint - To assess the correlation between pleural fluid parameters with ultrasound and medical thoracoscopic finding. - To assess the optimal Pf ADA cut-off value to differentiate TBE from MPE in our region.

NCT ID: NCT05923515 Recruiting - Clinical trials for Malignant Pleural Effusion

A Phase I Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion

Start date: May 22, 2023
Phase: Phase 1
Study type: Interventional

A Phase I, Open, Multicenter Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion

NCT ID: NCT05872126 Recruiting - Clinical trials for Malignant Pleural Effusion

Video Assisted Thoracoscopic Surgery (VATS) - Surgical Pleurodesis vs Tube Drainage in Management of Malignant Pleural Effusion (MPE)

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

Malignant Pleural Effusion (MPE) is considered to be a common presentation at malignant tumors representing 15% of all cancer cases. It carries a burden on our patients with dyspnea being the most common symptom in most of cases. Management of symptomatic malignant pleural effusion remains to be a point of debate. Data available from literature shows conflicting results lacking high quality evidence which necsscitates further research work. Options differs to include chemical pleurodesis using medical or surgical talc poudrage or slurry. Surgical intervention with abrasion pleurodesis or pleurectomy using VATS approach has been used in many studies. Using indwelling pleural catheters (IPCs) has also proved comparable efficacy at many clinical trials. In this study we want to help answering this question so that we can add to the current knowledge aiming to offer the best care for those patients

NCT ID: NCT05620329 Recruiting - Breast Cancer Clinical Trials

UNC Pleural Fluid Registry

Start date: January 24, 2018
Phase:
Study type: Observational [Patient Registry]

Research with biospecimens such as blood, tissue, or body fluids can help researchers understand how the human body works. Researchers can make new tests to find diseases, understand how treatments work, or find new ways to treat a disease. The purpose of this study is to collect biospecimens for research from patients with known or suspected lung cancer. The information learned from the biospecimens may be used in future treatments. The purpose of this protocol is to create a pleural fluid registry for use in future studies.

NCT ID: NCT05565014 Recruiting - Clinical trials for Malignant Pleural Effusion

Safety and Efficacy Study of Virus Activated Killer Immune Cells (VAK) for Malignant Pleural and Peritoneal Effusion

Start date: July 24, 2020
Phase: Early Phase 1
Study type: Interventional

Theory of VAK: 1. Immune cells (T cells for example) of cancer subjects may be domesticated by the tumor microenvironment, and have low efficacy to kill cancer cells. They could be restimulated by virus antigen, and play a powerful tumor killing role while intrapleural to subjects. 2. Releasing of tumor-associated antigen could induce specific anti-tumor immune response. Preparation of VAK: 1. Separate the immune cells and tumor cells from Malignant Pleural and Peritoneal Effusion. 2. Incubate the immune cells with inactivated viruses and tumor cells. 3. Wash to remove impurities. 4. Intrapleural the immune cells to patients

NCT ID: NCT05372055 Completed - Clinical trials for Malignant Pleural Effusion

Malignant Pleural Effusions: Evaluating the psYchosocial Impact of Indwelling Pleural Catheters on Patients

MY-IPC
Start date: May 9, 2022
Phase:
Study type: Observational

The purpose of this study is to better understand the impact that Indwelling Pleural Catheters have on patients with malignant pleural effusions from a psychosocial point of view.

NCT ID: NCT05330065 Not yet recruiting - Clinical trials for Malignant Pleural Effusion

A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion

Start date: August 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Patients with a variety of malignancies can develop malignant pleural effusion (MPE). MPE can cause significant symptoms and result in a marked decrease in quality of life and a poor prognosis. MPE is primarily considered as an immune and vascular manifestation of pleural metastases. The combined use of anti-angiogenic therapy and immunotherapy may be a promising strategy for MPE. This is a Phase Ib/II clinical trial to evaluate the safety and tolerability of administering bevacizumab and camrelizumab into the intrapleural space of subjects with malignant pleural effusion through a pleurX catheter.

NCT ID: NCT05278975 Recruiting - Mesothelioma Clinical Trials

Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

Start date: March 31, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, non-randomized, multicenter, translational Phase 1/2 dose-escalation and expansion study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of RSO-021 after intrapleural (IP) administration in patients with malignant pleural effusion (MPE) (non-mesothelioma) and MPE from mesothelioma.